Dihydromyricetin is a plant compound sold as a dietary supplement mainly for hangovers and, increasingly, liver, metabolic and healthy-aging benefits. Its most credible signals are modest liver-test and blood sugar improvements in fatty liver disease or type 2 diabetes, from a few small, short trials. Hangover results disagree; aging findings are laboratory and animal only. Safety looks reassuring so far; open questions: medicine interactions, drowsiness with sedatives, heavier drinking. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 7–55 U/L | Expected to fall; liver safety check |
| AST | Not specified in the ER | Paired with ALT and GGT |
| GGT | 8–61 U/L | Expected to fall |
| Fasting glucose | 70–99 mg/dL | Expected to fall; safety check with diabetes drugs |
| HbA1c | 4.0–5.6% | Expected to fall |
| LDL cholesterol | No established target; track change from own baseline | Expected to fall |
| Apolipoprotein B | Not specified in the ER | Paired with LDL cholesterol |
| Cystatin C | 0.5–1.0 mg/L | Expected to fall in type 2 diabetes |
| Drug trough level (tacrolimus, cyclosporine, digoxin) | No established target; compare with the level before starting DHM | Safety check |
Cadence: Baseline panel before starting; drug levels and glucose checks at 1–2 weeks for those on interacting medicines; full panel at 3 months, then every 6–12 months while use continues